SEC Form 4 · accession 0001179110-17-010226
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin F McLaughlin
Officer — SVP, CFO and Treasurer
Period of report
Jul 5, 2017
Accepted (ET)
Jul 7, 2017 · 4:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 5, 2017 | M | 3,150 | $5.28 | A | 80,950 | D | |
| Common Stock | Jul 5, 2017 | M | 18,750 | $7.12 | A | 99,700 | D | |
| Common Stock | Jul 5, 2017 | S | 34,400 | $32.00 | D | 65,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $5.28 | Jul 5, 2017 | M | 3,150 | D | — | Dec 16, 2021 | Common Stock | 3,150 | 6,250 | D |
| Option to Purchase Common StockF2 | $7.12 | Jul 5, 2017 | M | 18,750 | D | — | Dec 12, 2022 | Common Stock | 18,750 | 0 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.